Dual-Engineered Dendritic Cell Derived Small Extracellular Vesicles Couple T Cell Priming with Checkpoint...

Area of Science:

• Biomedical Engineering
• Immunology
• Nanotechnology

Background:

• Cancer immunotherapy, including immune checkpoint blockade (ICB), has advanced treatment but faces challenges with cell-based therapies' complexity and cost, and ICB agents' stability and T cell selectivity.
• Existing immunotherapies require improvements in targeted delivery, stability, and efficacy for broader clinical application.

Purpose of the Study:

• To develop an engineered dendritic cell derived small extracellular vesicle (DC sEV) nanoplatform for combinatorial immunotherapy.
• To achieve in situ T cell activation and checkpoint reprogramming using DC sEVs.
• To establish a targeted, scalable, and cell-free immunotherapy platform.

Main Methods:

• Engineered dendritic cell derived small extracellular vesicles (DC sEVs) were developed.
• DC sEVs were functionalized for high efficiency cargo loading and selective delivery of immune checkpoint blockade (ICB) payloads to T cells.
• In vitro and in vivo studies were conducted to evaluate the efficacy of the DC sEV platform.

Main Results:

• The DC sEV nanoplatform demonstrated preserved intrinsic dendritic-cell immunobiology, enabling antigen presentation and potent T cell activation.
• Selective delivery of ICB payloads to T cells resulted in dual reprogramming, sustaining effector function and amplifying antitumor immunity.
• The approach reduced cancer cell viability by 44.05% in vitro and achieved 82.12% tumor growth inhibition in vivo.

Conclusions:

• Engineered DC sEVs represent a promising cell-free immunotherapy platform for combinatorial cancer treatment.
• This nanoplatform offers a targeted and scalable approach to enhance T cell-mediated antitumor immunity.
• The developed DC sEVs overcome limitations of current immunotherapies, paving the way for improved cancer therapies.